Pseudopseudohypoparathyroidism (PPHP) is a rare genetic disorder that is characterized by a range of physical and psychological symptoms. It is caused by a mutation in the GNAS gene, which is responsible for the production of the enzyme guanine nucleotide-binding protein (G-protein). The mutation results in a decrease in the activity of the enzyme, leading to a disruption of the normal functioning of the parathyroid glands and other endocrine organs. The symptoms of PPHP vary from person to person and can range from mild to severe. These symptoms include short stature, obesity, delayed puberty, skeletal deformities, hypocalcemia, and mental retardation. Although the exact cause of PPHP is still unknown, research has revealed that it is likely due to a combination of genetic and environmental factors.
Pseudopseudohypoparathyroidism (PPHP) is a rare genetic disorder that is caused by a mutation in the GNAS gene. The GNAS gene is responsible for the production of the enzyme guanine nucleotide-binding protein (G-protein). This enzyme is responsible for the regulation of the parathyroid glands and other endocrine organs. When the enzyme is not functioning properly, it can lead to a disruption in the normal functioning of the parathyroid glands. This disruption can lead to a range of physical and psychological symptoms.
The symptoms of PPHP vary from person to person and can range from mild to severe. The most common symptoms include short stature, obesity, delayed puberty, skeletal deformities, hypocalcemia, and mental retardation. Other symptoms may include seizures, hypotonia, hypoglycemia, hypothyroidism, and kidney stones.
The diagnosis of PPHP is made through a combination of physical examination, laboratory tests, and genetic testing. Physical examination may reveal short stature, obesity, skeletal deformities, and delayed puberty. Laboratory tests may reveal low levels of calcium in the blood, as well as elevated levels of parathyroid hormone. Genetic testing is used to confirm the diagnosis of PPHP, as it can detect the mutation in the GNAS gene that is responsible for the disorder.
The treatment of PPHP is aimed at managing the symptoms and preventing complications. Treatment may include hormone replacement therapy, calcium and vitamin D supplementation, and lifestyle modifications. In some cases, surgery may be necessary to correct skeletal deformities or to remove kidney stones.
The complications of PPHP can vary from person to person, but may include delayed growth and development, skeletal deformities, kidney stones, and mental retardation. It is important for people with PPHP to be monitored closely by their doctor in order to detect any complications early and to prevent them from worsening.
Pseudopseudohypoparathyroidism (PPHP) is a rare genetic disorder that is caused by a mutation in the GNAS gene. The symptoms of PPHP vary from person to person and can range from mild to severe. Diagnosis of PPHP is made through a combination of physical examination, laboratory tests, and genetic testing. Treatment of PPHP is aimed at managing the symptoms and preventing complications. Complications of PPHP can include delayed growth and development, skeletal deformities, kidney stones, and mental retardation. It is important for people with PPHP to be monitored closely by their doctor in order to detect any complications early and to prevent them from worsening.
1.
FDA Leaders Explain Their Choice Regarding Cancer Risk Warning in CAR-T Investigation.
2.
Why breast cancer survivors don't take their medicine, and what can be done about it.
3.
MRI can save rectal cancer patients from surgery, study suggests
4.
Targeted radiation offers promise in patients with metastasized small cell lung cancer to the brain
5.
EBV Screening Tied to Lower Nasopharyngeal Cancer Mortality Risk
1.
Modern Oncology Unveiled with Treatment Innovations and Personalized Cancer Care
2.
The Mysterious World of Petechiae: Exploring Causes and Treatments
3.
The latest Hematocrit: An Overview of Red Blood Cell Health
4.
Toripalimab + Nab-Paclitaxel in PD-L1+ TNBC: Phase 3 TORCHLIGHT Trial Results
5.
AI and Optical Advances: Evolving Blood Cell Morphology Observation in Hematology
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Managing ALK Rearranged Non-Small Cell Lung Cancer with Lorlatinib - Part II
2.
From Relapse to Remission : Chasing the Invisible and Redefining Long-Term Survival in Adult R/R B-Cell ALL
3.
Post Progression Approaches After First-line Third-Generaion ALK Inhibitors
4.
Virtual Case Study on Deep Vein Thrombosis (DVT) - An Initiative by Hidoc Dr.
5.
Navigating the Complexities of Ph Negative ALL - Part I
© Copyright 2025 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation